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Introduction
Both breast cancers and hyperplastic lesions of prolifera-
tive breast disease originate from epithelial cells of the ter-
minal duct lobular unit [1]. Although cancer development
proceeds through a multistep process in which epithelial
cells undergo transformation as a result of multiple hits
(genetic model), it is becoming increasingly evident that
discrete genetic alterations in epithelial cells alone cannot
explain multistep carcinogenesis whereby tumor cells are
able to express diverse phenotypes during the complex
phases of tumor development and progression. Several
lines of evidence suggest that concomitant changes also
occur in cells surrounding the epithelial neoplasms [2].
The epigenetic model posits that the host microenviron-
ment exerts an initial inhibitory constraint on tumor growth
that is followed by acceleration of tumor progression
through complex cell–matrix interactions with the host
stroma. Breast stroma accounts for more than 80% of the
resting breast volume [3]. The stroma or the supportive
platform for the epithelial layer is composed of fibroblasts,
endothelial cells, smooth muscle cells, adipocytes, inflam-
matory cells, nerve cells and a macromolecular network of
proteoglycans and glycoproteins collectively termed the
extracellular matrix (ECM). Factors required for premalig-
nant progression, growth of primary cancer as well as
invasion and metastasis are all altered by stromal interac-
tions. The present review will focus on the function of the
stroma in regulation of epithelial growth, in regulation of
morphogenesis and in regulation of epithelial plasticity.
A role for stromal cells in carcinogenesis has been sug-
gested from studies of embryological development where
instructive and permissive interactions, along with genetic
factors, are required for programming and maintaining
epithelial structure and function. The embryonic epithelial
and instructive mesenchymal cells engage in a reciprocal
molecular dialog that ensures proper organ development
and function [4,5]. The permissive adult counterparts of
these epithelial and stromal interactions are believed to
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provide the regulatory signals that maintain homeostasis.
Malignant transformation of adult epithelial cells disrupts
such homeostatic regulation, including the control of
tissue architecture, adhesion, cell death and proliferation.
The importance of epigenetic constraints and their
impacts on the expression of the genetic machinery of the
cancerous epithelium has been demonstrated by observa-
tions that tumors prefer to grow and metastasize from
orthotopic sites rather than from ectopic sites [6,7].
Hormonal regulation by the stromal
compartment
The fibroblast is a major cell type of the stromal compart-
ment and is intimately involved in orchestrating the stromal
half of the dialog with the epithelium in maintaining tissue
homeostasis [8,9]. Alterations in fibroblasts in the stroma
adjacent to transformed epithelial cells have been docu-
mented in several tumor systems [10–12]. These include
alterations in growth characteristics and in migratory
potential, and altered expression of growth factors such as
platelet-derived growth factor, insulin-like growth factor I
and insulin-like growth factor II, transforming growth factor
beta, hepatocyte growth factor and keratinocyte growth
factor. However, the contribution of these stromal alter-
ations to tumor development and growth has not been
fully elucidated.
Results of tissue recombination studies utilizing epithelium
and stroma from wild-type and estrogen receptor (ER)
knockout mice have demonstrated that epithelial steroid
receptors are neither necessary nor sufficient for hormonal
regulation of epithelial proliferation. Instead, hormonal reg-
ulation of epithelial proliferation is a paracrine event medi-
ated by ER-positive stromal cells [8]. Although these data
signify the direct role that stroma plays in the control of
hormone-mediated epithelial cell proliferation, these
results are not completely applicable to humans as human
breast stromal cells are devoid of ER [13]. This species-
specific difference in stromal ER expression implies possi-
ble fundamental differences in regulation of epithelial
growth and morphogenesis by the stroma between
species. An emerging concept is that aromatase-mediated
estrogen synthesis in stromal fibroblasts and/or tumor
epithelial cells acts in a paracrine manner or an autocrine
manner, respectively, to influence breast tumor growth
[14]. Thus, in the early stages of breast cancer, a probable
role for stromal fibroblasts is the local production of estro-
gen so that a paracrine mechanism dependent on estro-
gen/ER levels can drive epithelial expansion.
With neoplastic progression, this requirement for an exter-
nal supply of estrogen may be replaced or additionally sat-
isfied by production of estrogen by the cells themselves
(autocrine action). Although the source of estrogen may
be different in mice versus humans, an important implica-
tion is that these tumors may initially respond to endocrine
perturbations as they are either estrogen dependent or
estrogen responsive. In the case of estrogen-independent
breast tumors, further growth of cancer cells may be
achieved by autocrine action of autostimulatory growth
factors that act either constitutively or under the positive
control of estrogen. It is not clear, however, how hormonal
regulation of growth factor networks is altered during
tumor progression. Can changes in the regulation of
stromal versus epithelial compartments by hormones have
a role in the emergence of estrogen-independent epithelial
growth?
Much work is clearly needed to clarify and define the hor-
monal integration and control of growth factor networks
in vivo. It is apparent, however, that hormones can target
both the epithelium and the stroma, and that a complex
interplay exists among hormones and growth factors tar-
geting these compartments. Variations in hormonal sensi-
tivity resulting from receptor loss, alterations in estrogen
synthesis that lead to differences in local estrogen levels,
an altered ECM or altered stromal–epithelial interactions
can thus lead to altered regulation of signaling mecha-
nisms, and hence to disruption of normal regulation of pro-
liferation and differentiation by growth factors [15].
Irregularities in the constituents of the stromal–epithelial
milieu or aberrations in their interactions can induce
genomic instability, can enhance tumor cell proliferation,
and can drive both metastatic spread and progression to a
hormone-refractory state. The inductive stroma may thus
be more than a source of soluble growth factors and/or
ECM to breast epithelial cells. The stroma may serve as a
driving force to promote tumor progression by providing a
platform to generate tumor cell heterogeneity [16–18].
The ECM and function
The ECM acts in several ways to modulate cell morphol-
ogy and proliferation, acting as a substrate to which cells
can adhere and as a reservoir of growth factors. The ECM
is connected to the nucleus by a network of protein mole-
cules that include transmembrane adhesion proteins, the
cytoskeleton and the nuclear matrix. The matrix networks
are different between normal and tumor cells, and modifi-
cation of the ECM induces alterations in the composition
of the nuclear matrix [19].
Studies utilizing transgenic mice have shown that the
development of experimental mammary tumors is gov-
erned by a common epigenetic process; the progressive
disruption of the glandular microenvironment [20]. Pro-
gressive and cumulative architectural changes in the
transgenic glands often mimic those occurring during clin-
ical breast cancer progression. These include multilayer-
ing of the epithelium in premalignant hyperplastic lesions,
a more rare intraepithelial cellular disorganization that
often leads to obliteration of the central lumen in nonmalig-
nant carcinomas in situ, and an even more infrequent132
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migration of epithelial-derived tumor cells into the sur-
rounding stromal microenvironment in invasive carcinomas
[21]. This increasing rarity of each architectural transfor-
mation suggests that microenvironmental suppression
becomes more stringent as tumor progression proceeds.
A major epigenetic modulator of this suppression is the
ECM [20], whose components are critical for enabling
cells to determine their orientation and morphology.
Laminin-mediated integrin signaling has been described to
play an important role in apical/basal polarization of
epithelial cells, in formation of a central lumen and in
expression of a differentiation-specific β-casein gene
product [22–24]. Perturbations in the production, deposi-
tion and degradation of the ECM occurring during neo-
plastic transformation and progression have been
implicated to arise from alterations in the stromal response
[25].
Stromal dominance of neoplastic phenotypes
Observations utilizing two-dimensional cell cultures in vitro
have been critical in elucidating the genetic programs and
signaling pathways that mediate the proliferation and hor-
monal response of malignant epithelial cells in breast
cancers. However, cancer development is vastly more
complex than simple autocrine dysregulation of epithelium.
Cooperative paracrine interactions among diverse cell
types in organized tissue structures are imperative for the
determination of epithelial differentiation, proliferation and
morphology. Understanding of the role of such interac-
tions in normal human breast function and in breast
cancers has been greatly facilitated by recent improve-
ments in in vitro culture systems that recapitulate differen-
tiated and transformed epithelial cell phenotypes.
Using a three-dimensional culture assay, developed with a
reconstituted basement membrane, Weaver and col-
leagues [26,27] demonstrated that the malignant pheno-
type of human breast cancer cells could be reversed by
correcting ECM-integrin signaling. Various changes in
integrin expression have been noted in breast carcinomas,
although there are conflicting data with regard to the spe-
cific integrin subunits that are affected [28]. α6β4-integrin
signaling normally acts to initiate apical/basal polarity in
response to contact with laminin in the basement mem-
brane [29]. When cells become transformed, however,
chronic activation of β1-integrin signaling is seen at the
expense of α6β4-integrin, and cells no longer respond to
epigenetic constraints imposed by the ECM [29]. Prolifer-
ation is controlled, morphogenesis is restored and tumori-
genesis is dramatically reduced when this integrin
switching is reversed, despite the fact that genetic abnor-
malities acquired by tumor cells during progression persist
[27,29]. These data suggest that appropriate integrin sig-
naling is one of the microenvironmental epigenetic effec-
tors that can act dominantly, by overriding genetic
constraints in the epithelium, to suppress the expression
of the breast cancer phenotype.
Further evidence for the dominant role of microenviron-
mental epigenetic effectors and their ability to influence
epithelial cell plasticity has come from previous studies.
Clear differences in epithelial growth and morphogenesis
were observed when premalignant breast cells were
cocultured on reconstituted basement membrane with
normal breast fibroblasts versus tumor-derived breast
fibroblasts [30]. Breast epithelial cells and breast fibrob-
last cells cultured separately over agar, to prevent adher-
ence to the surface, organize into compact cellular
spheroids. Both epithelial and fibroblast spheroids lack
organization, although fibroblast spheroids exhibit func-
tional differentiation forming a meshwork of type IV colla-
gen (R Pauley, S Santner, L Tait, unpublished
observations, 2002). In cocultures there is commonly
compartmentalization with central fibroblasts and outer
epithelial cells. Again epithelial morphogenesis is not
evident, but fibroblast-differentiated function is indicated
by a type IV collagen meshwork.
In the context of the present review, functionality for aro-
matase-mediated estrogen synthesis in fibroblast spher-
oids or in three-dimensional cocultures with epithelial cells
can be postulated based on regulated aromatase activity
in breast fibroblast monolayer cultures [14]. Cocultures
over a reconstituted basement membrane and over agar
exhibit similarities for epithelial fibroblast compartmental-
ization. Fundamental differences occur, however, because
only cocultures over a reconstituted basement membrane
exhibit epithelial morphogenesis, growth regulation and
differentiation. These differences indicate that two funda-
mental components, the reconstituted basement mem-
brane and the fibroblast, together influence epithelial
neoplastic phenotype. In addition, the tissue origin of
breast fibroblasts influences the epithelial neoplastic phe-
notype. On a reconstituted basement membrane, cocul-
ture of premaligant breast cells with normal fibroblasts
resulted in only weak induction of epithelial growth and
morphogenesis, but similar cocultures with benign or
tumor-derived fibroblasts resulted in induction of highly
proliferative ductal–alveolar morphogenesis. Interestingly,
besides inhibiting morphologic transformation of premalig-
nant breast cells, reduction mammoplasty-derived fibro-
blasts were also found to have the ability to suppress
estrogen responsiveness of premalignant breast cells.
Coculture with tumor-derived fibroblasts not only favored
inductive morphogenetic and mitogenetic effects on pre-
malignant breast cells, but also supported their respon-
siveness to estrogen [30].
These data suggest that breast fibroblasts derived from
normal or tumor tissues have the ability to override/accen-
tuate the genetic constraints imposed by the epithelial133
cells. It is interesting to note that, despite the presence of
a variety of ECM proteins and factors in the reconstituted
basement membrane matrix, the differentiation effects
induced by the stroma are elicited only when premalignant
breast cells are cocultured with organ-specific fibroblasts.
These findings indicate a specific requirement for ECM
molecules that are assembled or laid down by the mes-
enchyme for modeling of mammary glandular architecture,
and they underscore the specific demands that must be
met for establishment of productive stromal–epithelial
interactions both by contact-dependent and soluble
factor-mediated mechanisms.
Genetic basis for stromal contribution to
neoplastic phenotype
Normal mammary terminal ductal-lobular units (TDLUs)
adjacent to invasive breast cancers have been demon-
strated to contain similar loss of heterozygosity (LOH),
whereas TDLUs distant from cancerous components
lacked such molecular heterogeneity [31]. These findings
suggest that molecular alterations that characterize inva-
sive breast carcinomas either may occur very early during
progression or, at least in part, may represent a ‘field
effect’ predictive of sensitivity to carcinogenic insult. The
contribution of the stroma to early events in carcinogene-
sis, in the absence of exogenously induced mutagenic
events in mammary epithelial cells, was demonstrated by
significant increases in tumor incidence and by growth of
COMMA-D cells transplanted to cleared mammary glands
in irradiated hosts as compared with unirradiated animals
[32]. The radiation-induced effects on stromal microenvi-
ronment were local rather than systemic because the
tumors arose only when COMMA-D cells were trans-
planted to the irradiated side of animals [32].
Further support for the concept that the stroma is not an
innocent bystander during epithelial carcinogenesis, but is
an integral player in maintenance of cellular and tissue
architecture, and perhaps a component of the ‘field’, has
come from recent studies that have shown the presence of
concurrent and independent genetic alterations in stromal
and epithelial cells of human breast carcinomas [33,34].
The LOH frequency in the stroma close to cancer was
found to range from 10 to 66.5% for ductal carcinoma
in situ and from 20 to 75% for intraductal carcinomas,
whereas no LOH was revealed in epithelial or stromal com-
ponents of breast tissues from women without any breast
disease [33]. These intriguing findings not only support the
concept of stromal–epithelial interactions in the develop-
ment and progression of breast neoplasia, but also
suggest that genetic alterations in the stroma may signifi-
cantly contribute to neoplastic phenotypes.
It is possible that some of these alterations may function in
a dominant fashion while others may require the coopera-
tion of parallel or multiple complex alterations at other sites
to facilitate progression [35]. A more recent study has
reported the presence of a lower frequency of LOH in
stromal cells as compared with their epithelial counter-
parts microdissected from invasive adenocarcinomas [36].
These data suggest that stromal genetic alterations are
either not dominant or may exert an indirect effect on the
adjacent epithelium, or that they only exert an effect in col-
laboration with others to influence the overall process of
tumorigenesis.
Alternatively, the presence of few, but critical, alterations
in the stroma may be sufficient to play a key role in the reg-
ulation of epithelial proliferation and morphogenesis as
stromal cells play a critical role in the production, assem-
bly and dissolution of the ECM [18,37]. Consequently, the
presence of even relatively few, but critical, alterations in
stromal cells might greatly influence epithelial growth, hor-
monal response, tumor invasion and/or dissemination
through ECM remodeling [38–40]. If so, intratumor and
intertumor heterogeneity of human breast cancer should
be viewed not only as a result of phenotypic drifting
arising from genomic instability, but also from the point of
view of their impact in concert with the microenvironment
and on the inherently dominant ability of the stroma to
influence epithelial plasticity. The identification of critical
stromally derived genes will be pivotal to the design of
novel therapeutic strategies to selectively target the
stromal microenvironment and to induce conversion of
cancer cells to a benign or less aggressive state.
Conclusions
Breast neoplasia has traditionally focused on the tumori-
genic transformation of breast epithelial cells resulting
from the accumulation of genetic alterations in epithelial
cells that influence fundamental processes including pro-
liferation and organization. Nevertheless, concurrent struc-
tural, cellular, functional and genetic alterations occur in
the surrounding stroma. These changes in the stroma alter
the normal stroma’s influence on the fundamental epithe-
lial cell characteristics of growth, morphogenesis and
plasticity to contribute to the development of the tumori-
genic epithelial phenotype. For example, alterations to
fibroblasts adjacent to the transformed epithelium involve
proliferation, growth factor expression and even local
estrogen production. These alterations of fibroblast func-
tion are demonstrated to exhibit a dominant regulatory role
via microenvironmental epigenetic effectors on the pheno-
type of breast epithelial cells.
Although details of concurrent and independent genetic
alterations in human breast epithelial and stromal cells
remain to be resolved, there is now substantive experimen-
tal evidence that stromal cells and the ECM interact both
directly and indirectly to influence the phenotype of trans-
formed breast epithelial cells. This provides the opportu-
nity to identify and use new therapies that antagonize the
Available online http://breast-cancer-research.com/content/5/2/130134
tumor-promoting influence of a tumor’s stromal cells to
reduce the tumorigenicity of transformed, and potentially
invasive, breast epithelial cells. 
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